NATCO receives FDA approval for Vidaza for USA market
June 28, 2017 | Wednesday | News
Vidaza is anti-cancer chemotherapy drug that is used for myelodysplastic syndrome (MDS)
Source: Pixabay
Natco pharma limited has announced the final approval for Abbreviated New Drug Application (ANDA) from the U.S. Food and Drug Administration (FDA) for Azacitidine for Injection, a generic version of Vidaza by Celgene Corporation.
Vidaza is anti-cancer chemotherapy drug that is used for myelodysplastic syndrome (MDS). Vidaza generated total combined sales of $188 million for the twelve-month period ending April, 2017, based on industry sales data.
According to the notification given on company’s website, “NATCO and its marketing partner Breckenridge Pharmaceutical, Inc. (BPI) plan to launch this product in the USA market in the near future”
